Aptar announced that it is seeking FDA emergency use authorization (EUA) for its N95 mask decontamination process with ActivShield. The N95 masks (produced by Honeywell (NYSE:HON) and 3M (NYSE:MMM)) are in short supply and high demand during the COVID-19 pandemic. To disinfect the masks, a small strip of Aptar’s ActivShield is placed alongside an N95 mask inside a […]
Aptar wins FDA clearance for ready-to-use seizure treatment device
AptarGroup today said it won FDA approval for its Unidose Liquid System that treats acute repetitive seizures in people who have epilepsy. The Unidose Liquid System is a device that delivers a nasal rescue treatment that is ready-to-use when and where a seizure cluster occurs. Get the full story on our sister site, Drug Delivery Business […]
Aptar Pharma’s two-dose nasal spray device to deliver epinephrine
Aptar Pharma has entered an agreement for Bryn Pharma to use Aptar’s Bidose (BDS) nasal device to deliver Bryn’s epinephrine nasal spray (BRYN-NDS1C). Crystal Lake, Ill.-based Aptar’s Bidose tech enables two-shot nasal drug delivery and will replace the need to carry two epinephrine auto-injectors, according to the companies. Last March, Aptar won FDA approval to use Bidose for a […]
